What type of study is this?

December 8, 2025BloodOpen Access

Antiviral efficacy of EBV and CMV bispecific cytotoxic t lymphocytes following allogeneic hematopoietic stem cell transplantation

View Full Paper

Ask AI

Bookmark

Cumulative complete response rates were observed at 56.5% and 78.3% for EBV/CMV infections at weeks 4 and 8, respectively.
Following treatment, no acute or long-term adverse effects were reported, confirming the safety profile.
Median follow-up of 175 days indicated a 2-year overall survival rate of 61.8% in the cohort.
Antiviral efficacy demonstrates significant reductions in viral loads, indicating effective treatment for viral infections.

No takes yet. Share an insight, caveat, or question.

Retrospective analysis shows bispecific CTLs reduce viral loads in allo-HSCT recipients, suggesting improved outcomes.

Zhang et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark